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Table. Clinical Outcomes at 12 Months Stratiﬁed According to rSS and bSS
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ID-TVF, n (%) 16 (2.87) 28 (4.31) 63 (9.75) 0.1811 0.0001 <0.0001 <0.0001
Cardiac Death,
n (%)
0 (0.00) 3 (0.46) 6 (0.93) 0.2536 0.3411 0.0334 0.0661
TVMI, n (%) 8 (1.43) 19 (2.93) 34 (5.26) 0.0802 0.0339 0.0003 0.0008
ID-TVR, n (%) 8 (1.43) 7 (1.08) 30 (4.64) 0.5787 0.0001 0.0015 <0.0001
Residual Syntax
score
Low (rSS¼0) Mid
(0<rSS<¼5)
High (rSS>5) p-Value
n¼1190 n¼403 n¼258 * Low vs. Mid * Mid vs. High * Low vs. High All Groups
ID-TVF, n (%) 52 (4.37) 28 (6.95) 26 (10.08) 0.0405 0.1518 0.0002 0.0008
Cardiac Death,
n (%)
2 (0.17) 3 (0.74) 4 (1.55) 0.1064 0.4406 0.0110 0.0091
TVMI, n (%) 27 (2.27) 17 (4.22) 17 (6.59) 0.0390 0.1783 0.0002 0.0010
ID-TVR, n (%) 25 (2.10) 9 (2.23) 10 (3.88) 0.8737 0.2176 0.0924 0.2317
* p value <0.0167 was considered statistically signiﬁcant.
Table. Clinical Outcomes at 1- and 2-Year
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Clinical Follow-Up,
% (n)
99.6 (226) 100 (231) 0.50 99.6 (226) 100 (231) 0.50
Dual Antiplatelet
Therapy,
% (n/N)
92.4 (208/225) 93.0
(213/229)
0.82 24.9
(56/225)
27.8
(63/227)
0.49
Death, % (n) 0.4 (1) 0.9 (2) 1.00 0.4 (1) 0.9 (2) 1.00
Cardiac Death 0.4 (1) 0 (0) 1.00 0.4 (1) 0 (0) 1.00
Non Cardiac Death 0 (0) 0.9 (2) 0.50 0 (0) 0.9 (2) 0.50
Myocardial
Infarction, % (n)
1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50
Q Wave MI 0 (0) 0 (0) - 0 (0) 0 (0) -
Non Q Wave MI 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50
Target Vessel MI 1.3 (3) 1.7 (4) 1.00 1.3 (3) 1.7 (4) 1.00
Ischemia-Driven
TLR, % (n)
0.4 (1) 0.4 (1) 1.00 0.9 (2) 0.9 (2) 1.00
Any
Revascularization,
% (n)
1.8 (4) 4.8 (11) 0.07 2.2 (5) 6.1 (14) 0.04
*Device-Oriented
Composite
Endpoint (TLF), %
(n)
2.2 (5) 2.2 (5) 1.00 2.7 (6) 2.6 (6) 0.97
**Patient-Oriented
Composite
Endpoint, % (n)
3.5 (8) 7.4 (17) 0.07 4.0 (9) 8.7 (20) 0.04
Deﬁnite or
Probable Stent
Thrombosis, % (n)
0 (0) 0 (0) - 0 (0) 0 (0) -
*Device-Oriented Composite Endpoint (TLF) deﬁned as the composite of cardiac death, target
vessel MI, or ischemia-driven TLR.
**Patient-Oriented Composite Endpoint deﬁned as the composite of all cause death, all MI, or
any revascularization.
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SConclusions: In the multicenter TARGET I trial, the novel abluminal groove-ﬁlled
biodegradable polymer SES FIREHAWK was comparable to the durable polymer
EES XIENCE V with respect to the TLF and its components at two years for treating
patients with single de novo native coronary lesions. The incidences of clinical
endpoints were low in both groups. (ClinicalTrials.gov Identiﬁer: NCT01196819).
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Background: Previous studies demonstrated the safety and efﬁcacy of the 2nd
generation drug-eluting stent in treating patients with simple to complex coronary
lesions. The Syntax score has been proposed as a valuable tool to characterize the
coronary anatomy prospectively with respect to its complexity. However, the prog-
nostic value of baseline Syntax score (bSS) and residual Syntax score (rSS) in patients
with complex lesions treated by XIENCE V everolimus-eluting stent (Abbott
Vascular, Santa Clara, CA, USA) on adverse outcomes have not been validated.
Methods: SEEDS was a prospective, multicenter registry study designed to enroll up
to 1900 patients with small vessel (reference vessel diameter <¼ 2.75mm), long
lesion (length >¼ 25mm), or multivessel disease (>¼ 2 target vessels) suitable for
treatment with XIENCE V at 48 centers in China mainland, Macao and Taiwan. The
primary outcome was ischemia-driven target vessel failure (ID-TVF), deﬁned as the
composite of cardiac death, target vessel myocardial infarction (TVMI), or ischemia-
driven target vessel revascularization (ID-TVR) at 12 months. The bSS stratiﬁed
into low (<¼6), mid (>6 and <¼12) and high (>12) and rSS into low (<¼0), mid
(>0 and <¼5) and high (>5) tertiles were applied in all patients.
Results: The mean of bSS was 10.87  7.26, and after PCI the rSS was 2.18  3.97.
At 12 months the primary outcome ID-TVF and its components cardiac death, TVMI,
and ID-TVR were 5.95%, 0.47%, 3.32%, and 2.47%, respectively. The table shows
the clinical outcomes stratiﬁed according to rSS and bSS.B8 JACC Vol 62/18/Suppl B j October 27–NovembConclusions: Signiﬁcantly higher rates of 12-month ID-TVF were observed in the
highest baseline and residual Syntax score groups, indicating that baseline and
residual Syntax score might be the useful tools to predict clinical outcomes in complex
patients treating with 2nd generation everolimus-eluting stent (ClinicalTrials.gov
identiﬁer: NCT 01157455).Bifurcation and Left Main Stenting
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Background: In bifurcation lesions (15-20% of PCIs), results of PCI with balloon
expandable stents are often impaired by carina incomplete support, strut deformation,
malapposition, or excessive metallic burden when treated with 2 stents. Dedicated
stents were developed but they often require precise and difﬁcult positioning or
require to stent ﬁrst the side branch. There is thus a need for an easy to use stent in
most bifurcations and which follows guideline practice of main branch (MB) provi-
sional stenting, supporting carina with minimal disruption of the side branch (SB)
anatomy. The self-expanding STENTYS DES (Stentys, Paris, France) has dis-
connectable struts for side branch access and showed very high procedural success and
low MACE rate in the OPEN I trial.
Methods: The OPEN II prospective, multi-centric single-arm study assess the safety
and efﬁcacy at 6 and 12-months of the STENTYS Paclitaxel eluting stent in routine
coronary bifurcation stenosis. Key exclusion criteria were Medina class 0,0,1, chronic
total occlusion, unprotected left main, and STEMI as clinical presentation. SB stenting
was left to operator's discretion. The primary endpoint of the study is MACE at 6
months follow-up. Secondary endpoints include MACE rate at 12 months, targeter 1, 2013 j TCT Abstracts/ORAL/Bifurcation and Left Main Stenting
